tbuckley/cabot-search huggingface dataset:
AB1187 RELIABILITY AND VALIDITY OF THE CONE EVASION WALK TEST IN HIP OSTEOARTHRITIS
Authors: B. Unver, K. S. Kacmaz, V. Karatosun
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Hip osteoarthritis (OA) is associated with joint pain and stiffness, reduced balance, impeded mobility, and loss of functional independence [1]. Falls are the leading cause of fatal and nonfatal injuries among older adults and people with hip OA. Fall-related injuries and circumstances such as hip fractures and subsequent arthroplasty procedures put a significant burden on financial resources and healthcare systems [2]. Therefore, the identification and prevention of falls are easier, cheaper, and more effective for all parties in healthcare. The Cone Evasion Walk Test (CEW) is a dual-tasked performance measurement that was designed for evaluating dynamic balance, proactive gait control, and fall risk by assessing the ability to evade obstacles [3]. <h3>Objectives</h3> The aim of this study was to investigate the reliability and validity of the CEW in patients with hip OA and estimate the minimal clinically important difference (MCID) of the CEW. <h3>Methods</h3> Twenty-seven patients with hip OA were included in this study. Patients performed trials for the CEW and the Timed up and Go Test (TUG). Between the CEW trials, patients got to rest for an hour. <h3>Results</h3> The analysis showed that the CEW has excellent reliability and validity in hip OA (p&lt;0.001). The relative (ICC coefficient) and absolute (SEM and SRD95) reliability of the CEW were 0.95, 0.53, and 1.46 respectively. The Spearman correlation coefficient with the TUG was 0.65. <h3>Conclusion</h3> The CEW was shown to be effective in terms of evaluating the function, dynamic balance, mobility, and fall risk with an additional attention-demanding task in patients with hip OA. The low MCID value (1.46) provides a sensitive measure of alterations in a patient's condition. Therefore, the CEW may be a better assessor of the proactive gait control, fall risk, mobility, and dynamic balance activities in the everyday community than the existing performance measures. <h3>References</h3> [1]Smith TO, Higson E, Pearson M, Mansfield M. Is there an increased risk of falls and fractures in people with early diagnosed hip and knee osteoarthritis? Data from the Osteoarthritis Initiative. Int J Rheum Dis. 2018 Jun;21(6):1193–201. [2]Kim J, Foucher K. Fall experiences from the perspectives of people with osteoarthritis: in their own words. Disabil Rehabil [Internet]. 2022 [cited 2023 Jan 14]; Available from: https://pubmed.ncbi.nlm.nih.gov/36519505/ [3]Sjöholm H, Hägg S, Nyberg L, Rolander B, Kammerlind AS. The Cone Evasion Walk test: Reliability and validity in acute stroke. Physiotherapy Research International. 2019 Jan;24(1):e1744. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1405 POSTOPERATIVE RESULTS OF JOINT-PRESERVING SURGERY WITH MITCHELL’S OSTEOTOMY FOR HALLUX VALGUS DEFORMITY IN PATIENTS WITH RHEUMATOID ARTHRITIS
Authors: C. Yoshimura, T. Okano, S. Anno, Y. Yamada, K. Orita, K. Mamoto, Y. Sugioka, M. Tada, K. Inui, T. Koike, H. Nakamura
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> In recent years, joint-preserving surgery has become common surgical procedure for forefoot deformities in Japanese patients with rheumatoid arthritis (RA). Since arthritis contributes to hallux valgus deformity in patients with RA, the postoperative outcome may differ from that in patients with idiopathic hallux valgus (IHV) patients. <h3>Objectives</h3> In this study, we compared the postoperative results of Mitchell's osteotomy in patients with RA and IHV. <h3>Methods</h3> We evaluated 181 feet in 111 patients (52 feet in 34 patients with RA, 129 feet in 77 patients with IHV) who performed Mitchell's osteotomy surgery between January 2006 and September 2021 and followed-up more than one year. The hallux valgus angle (HVA) and intermetatarsal angle (IMA) were measured from standing X-ray images of the foot, before and after surgery and one year later, and the postoperative course of RA and IHV patients was compared. <h3>Results</h3> Preoperative HVA was 42° [20-73] in patients with RA and 40° [17-62] in patients with IHV, with no significant differences. Preoperative IMA was 14° [6-22] in patients with RA and 15° [7-23] in IHV patients, significantly smaller in the RA group (p&lt;0.01). HVA at 1 year was 7° [-21-34] in patients with RA and 9° [-24-38] in patients with IHV, with no significant differences. IMA at 1 year was 7° [0-18] in patients with RA and 8° [1-21] in patients with IHV, with no significant differences. The recurrence rate at 1 year postoperatively was 17.3% in patients with RA and 16.3% in patients with IHV, with no difference. Traditionally, metatarsal head resection has been performed for rheumatoid forefoot deformities. However, joint-preserving surgery is recently performed due to the improvement of anti-rheumatic drugs such as biological disease modifying drugs and Janus kinase inhibitors. Mitchell's osteotomy has been recommended for IHV as a joint-preserving surgery, as has Chevron osteotomy. The results of this study showed that Mitchell's osteotomy is useful treatment method for patients with RA as well as for patients with IHV. In addition, preoperative IMA in patients with rheumatoid forefoot deformity was significantly smaller than patients with IHV, but there was no difference in HVA. This suggests joint inflammation leads to lateral dislocation of proximal phalanx without metatarsal bone medialization. <h3>Conclusion</h3> Joint-preserving surgery with Mitchell's osteotomy was useful method for hallux valgus deformity in patients with RA. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1373 ARE FIBROMYALGIA AND/OR DEPRESSION THE MOST COMMON DIAGNOSES SEEN IN ROUTINE RHEUMATOLOGY CARE, ALBEIT AS SECONDARY DIAGNOSES, BUT WHICH MAY COMPLICATE CLINICAL ASSESSMENT, PROGNOSIS AND MANAGEMENT?
Authors: T. Pincus, J. Schmukler, T. Li, J. Block
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Fibromyalgia (FM) and depression (DEP) are common comorbidities in all primary rheumatic diagnoses, easily recognized in many patients, but often underestimated, particularly in patients who meet criteria for a primary rheumatic disease. Two screening indices to recognize FM and/or DEP are found within a 2-page multidimensional health assessment questionnaire (MDHAQ), FAST4 (fibromyalgia assessment screening tool) and MDS2 (MDHAQ depression screen) [1]. FAST4 agrees 90% with 2011 revised FM criteria, and MDS2 agrees 80% with reference HADS-D (hospital anxiety and depression scale–DEP). <h3>Objectives</h3> To analyze patients with different rheumatic diagnoses according to FAST4 and MDS2 as well as reference 2011 FM Criteria and HADS-D, to recognize those who screen positive for FM and/or depression. <h3>Methods</h3> The MDHAQ is a 2-page patient self-report questionnaire designed for routine care, completed by most patients with any diagnosis in 5-10 minutes at all visits to 2 academic rheumatology sites. The MDHAQ includes scores to calculate FAST4 and MDS2: the FM screen is positive (FAST4+) if 3/4 are present of: pain 0-10 visual numeric scale (VNS) ≥6/10, fatigue VNS ≥6/10, patient self-report 0-54 RADAI painful joint score ≥16/54, 60-symptom checklist (ROS) ≥16/60. The DEP screen is positive (MDS2+) if 0-3.3 DEP in the patient-friendly HAQ format is ≥2.2 OR DEP is + on ROS. The % of patients with various primary diagnoses, and % who screened positive or negative by FAST4, MDS2, 2011 revised FM criteria, or HADS-D was computed. <h3>Results</h3> Among 1,038 routine rheumatology care patients at 2 settings, 307 were FM+ by FAST4, 297 by 2011 FM criteria,295 DEP+ by MDS2, and 364 DEP+ by HADS-D. These prevalences were ≥28.0% according to FAST4 and MDS2 in all patients, as high as most prevalent primary ICD-10 diagnosis of 291 for rheumatoid arthritis (RA) (Table 1). Percentages of FM+ and DEP+ patients were within 12% for all diagnosis categories except for 6.3% of patients with primary FM (Table 1). <h3>Conclusion</h3> Non-somatic problems of FM and DEP are as common as any diagnosis seen in routine rheumatology care at 2 academic sites, albeit as secondary diagnoses in most patients. FM and/or DEP may complicate assessment, prognosis, and management of clinical status and explain poor responses to treatment in some patients. It is feasible to screen for FM and DEP on a single MDHAQ, completed by most patients in 5-10 minutes, as FAST4 and MDS2 indices, at any rheumatology site. <h3>Reference</h3> [1]Curr. Treat. Options Rheumatol 2021;7(3):161-81. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB0897 THE PRESENCE OF ANTI-U1-RNP ANTIBODY HAS A MILD BUT APPARENT IMPACT ON INTERSTITIAL LUNG DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS
Authors: Y. Ito, H. Fujimoto, Y. Yamamoto, A. Nakajima
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Interstitial lung disease (ILD) is the leading cause of systemic sclerosis (SSc)-related death[1]. With the availability of antifibrotic agents to slow the progression of SSc-ILD[2], it is important for clinicians to be aware of the antibody profile predicting the severity and progression of SSc-ILD. <h3>Objectives</h3> To determine the impact of anti-U1 ribonucleoprotein antibody (αRNPab) in addition to anti-topoisomerase 1 antibody (ATA) on SSc related interstitial lung disease (ILD). <h3>Methods</h3> Patients with SSc who visited Mie University Hospital between December 2020 to December 2021 were consecutively registered. The severity and progression of ILD on chest computed tomography (CT) were assessed based on the ILD and traction bronchiectasis (TBE) scores, evaluated by using established method [3] with minor modification. We hypothesized that ATA had the greatest impact on ILD, followed by αRNPab, and accordingly stratified patients into three groups: group 1, ATA-positive; group 2, αRNPab-positive; and group 3, double-negative. At registration, patient characteristics were compared according to the presence of ILD, and the severity of ILD were compared among three groups. For patients who had earlier CT scans available, ILD progression was assessed. <h3>Results</h3> Among 48 patients (ILD/non-ILD; n=25/23), αRNPab positivity was significantly higher in the ILD than in the non-ILD group (32%, 0%, p&lt;0.01). In 47 patients, the percentage of patients whose ILD score ≥ 20% was 83.3, 28.5 and 5.8% in groups 1, 2 and 3 (n = 6/7/34), respectively (p&lt;0.01). In 25 patients, the percentage of patients with progressive ILD whose ILD score increased by ≥ 5% was 80.0, 50.0 and 14.3% in groups 1, 2 and 3 (n = 5/6/14), respectively (p&lt;0.01). <h3>Conclusion</h3> The presence of αRNPab significantly affects the presence, severity and progression of SSc-ILD, although the effect is milder than that of ATA. <h3>References</h3> [1]Khanna D, et al. Arthritis Rheumatol 2022;74(1):13-27. [2]Distler O, et al. N Engl J Med 2019;380(26):2518-28. [3]Walsh SL, et al. Thorax 2014;69(3):216-22. <h3>Acknowledgements</h3> I have no acknowledThis work was supported by Nippon Boehringer Ingelheim Co., Ltd., Chugai Pharmaceutical Co., Ltd. and Mitsubishi Tanabe Pharma Corporation and AbbVie GK for the cost of anti-ARS antibody measurement. The design, execution, and interpretation of results for this study were entirely independent of these companies.gements to declare. <h3>Disclosure of Interests</h3> None Declared.
AB1269 HEARING LOSS – A RARE MANIFESTATION OF THE CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE
Authors: P. Bradna
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Calcium pyrophosphate dihydrate (CaPPD) deposition disease is a illness with a wide range of manifestations from acute gout-like episodic arthritis to an accentuated osteoarthritis picture. A common feature is the deposition of CaPPD crystals in tissues. Middle ear involvement is a rare manifestation of the disease, described in a few case reports. <h3>Objectives</h3> Middle ear involvement is a rare manifestation of the disease, described in a few case reports. <h3>Methods</h3> Histological examination of operating specimen. HRCT. <h3>Results</h3> 71-year-old man, athlete (tennis, cycling) underwent a partial menisectomy in 2008 for acute knee blockade, in October 2022 he suffered polytrauma after a traffic injury. Het is treated for arterial hypertension. He has never had inflammatory arthritis, joint problems he had only in connection with sports injuries. Last 12 months he has observed a gradually progressing hearing loss, mild dizziness and tinnitus. HRCT of a scull base demonstrated a left-sided osteoma with fixation to the malleus. Tumor mass was removed by surgery. Histology proved calcium pyrophosphate dihydrate crystals in the operating material. We have not demonstrated hyperparathyroidism, hypomagnesemia, or any other primary disease associated with CaPPD deposition. During subsequent X-ray examination, we found the chondrocalcinosis of the menisci of both knees. <h3>Conclusion</h3> Deposits of calcium pyrophosphate in the middle ear region are a rare manifestation of the calcium pyrophosphate dihydrate deposition disease. Clinically, progressive hearing loss may occur, morphologically resemble osteoma and may not be associated with other clinical signs of the underlying disease. <h3>Reference</h3> [1]Serrano MG et al: J Royal Soc Med open 2020;11:1-4 <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1151 COMORBIDITY IN PSORIATIC ARTHRITIS (COMPASS) – INCIDENCE OF DEPRESSIVE SYMPTOMS AND ASSOCIATED FACTORS
Authors: A. Avik, E. Waldheim, S. Geschwind, A. Antovic, V. Oke
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Patients with psoriatic arthritis (PsA) demonstrate increased prevalence of several comorbidities, including mental health conditions. <h3>Objectives</h3> Aim of the study was to investigate the prevalence of self-reported depressive symptoms (SRDS) and diagnosis of depression among PsA patients treated at Centre for Rheumatology, Stockholm and investigate associated clinical, laboratory and psychosocial parameters. <h3>Methods</h3> 71 patients were included from prospective cross-sectional COMPASS study. Information regarding disease activity (joint assessment, enthesitis (SPARCC), psoriasis body surface area (BSA)% and psoriasis area severity index (PASI)) were collected. Patient Health Questionnaire-9 (PHQ-9) was used to assess SRDS. Dermatology Life quality Index (DLQI) was used to assess impact of cutaneous symptoms. <h3>Results</h3> 72% of included patients were females, mean age 53.9 years (SD 12.7) and 75% were included at first visit. 52 patients reported a PHQ-9 score of none to mild depression (ND group) and 19 patients a score equal to moderate or severe depression (D group). The D group had significantly more severe somatic disease, including higher swollen (p=0.006) and tender joint counts (p=0.003), higher enthesitis score (p=0.012) and VAS score (p=0.004). Multivariate analyses showed a positive correlation between severity of SRDS and pain (ρ=0.51, p&lt;0.001), DLQI (ρ=0.40, p=0.001), tender/swollen joints (ρ=0.38, p-=0.001/ρ=0.34, p=0.004), enthesitis (ρ=0.27, p=0.032) and PASI (ρ=0.28, p=0.028). Patients reported that the mean time from the first joint symptom to the first visit to rheumatologist was 10.5 years (SD 13.2). Importantly, only those who received the PsA diagnosis and treatment later than 2 years since the onset of symptoms, reported depressive symptoms (PHQ&gt;10 (mild or more severe) or 14 (moderately or severe)). <h3>Conclusion</h3> In our cohort up to 26% of PsA patients display medium to severe depressive symptoms. Importantly, delay of 2 years to the first visit to rheumatologist is associated with SRDS. A severity of SRDS correlates with severity of somatic disease. <h3>Acknowledgements</h3> To the patients who participated and our research patient partner Ulla Sjölinder. <h3>Disclosure of Interests</h3> Aune Avik: None declared, Eva Waldheim: None declared, Sofia Geschwind: None declared, Aleksandra Antovic: None declared, Vilija Oke Speakers bureau: Novartis, Jansen, Lilly, Consultant of: Jansen, Lilly, Abbvie, UCB.
The International Network on Oesophageal Atresia (INoEA) consensus guidelines on the transition of patients with oesophageal atresia–tracheoesophageal fistula
Authors: Usha Krishnan, Michael W. Dumont, Hayley Slater, Benjamin D. Gold, David Seguy, Mikael Bouin, Rene Wijnen, Luigi Dall’Oglio, Mario Costantini, Anastassios C. Koumbourlis, Thomas A. Kovesi, Michael J. Rutter, Marlene Soma, Jessica Menzies, Audrey Van Malleghem, Nathalie Rommel, Michaela Dellenmark-Blom, Vuokko Wallace, Evelyn Culnane, Graham Slater, Frederic Gottrand, Christophe Faure
Journal: Nature Reviews Gastroenterology & Hepatology (2023)
AB1164 PSAQOL (PSORIATIC ARTHRITIS QUALITY OF LIFE) QUESTIONNAIRE: TRANSLATION, CULTURAL ADAPTATION AND VALIDATION INTO ARABIC LANGUAGE
Authors: R. Tekaya, L. Rouached, H. Hajji, A. Ben Tekaya, M. Jones, W. Hamdi, S. Nabil, L. Metoui, S. Bouden, O. Saidane, I. Mahmoud, L. Abdelmoula
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Psoriatic arthritis (PsA) is a multifaceted inflammatory disease that has a strong negativeimpact on the quality of life of patients. The Psoriatic Arthritis Quality of Life (PsAQoL)questionnaire was the first disease-specific patient derived instrument developed tomeasure the quality of life in patients with PsA. <h3>Objectives</h3> Our objective was to translate the PsAQol into Arabic language and evaluate its reliability and validity in patients with PsA. <h3>Methods</h3> This was a cross-sectional study including patients with PsA. A clinical and biologicalassessment of the patients was performed at inclusion. Translation of the original PsAQoL into Arabic was performed by professional bilingual and lay panel. Eight patients wereinterviewed to assess face and content validity. A separate sample of PsA patients (n=30)were invited to participate in a test-retest postal study in order to investigate reproducibilityand construct validity. One week separated the two administrations. The Arabic versionof Health Assessment Questionnaire (HAQ) was used as comparator instruments forconvergent validity. <h3>Results</h3> Face and content validity were satisfactory. The Arabic version of the PsAQoL was foundto be relevant, understandable and easy to complete in only a few minutes. One item wasexcluded (item 16). It showed having no correlation with neither the other 19 items nor the total score of PsAQol. The Arabic PsAQol had excellent internal consistency (Cronbach'sa=0.926), and test-retest reliability (r=0.982). There was a positive correlation betweenthe total score of the PsAQoL and the Arabic version of HAQ ((Spearman's r=0.838,p&lt;10-3). Exploratory factor analysis had extracted two factors explaining 55% of the totalvariance. <h3>Conclusion</h3> Nineteen items were selected to compose the Arabic version of PsAQoL which was foundto be relevant, understandable and has excellent reliability and construct validity. The newmeasure will be a valuable new tool for use in routine for patients' assessment. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1165 ULTRASOUND AS A TOOL FOR EARLY DETECTION OF JUXTAARTICULAR NEW BONE FORMATION IN PSORIATIC ARTHRITIS AND THE ASSOCIATION OF SELECTED BIOMARKERS WITH NEW BONE FORMATION
Authors: A. Knothe, K. G. Hermann, K. Frommer, A. K. Inderthal, C. Heck, M. Arnold, I. Tarner, W. Hermann, C. F. Meneses Villalba, E. Neumann, U. Müller-Ladner, R. Hasseli
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background:</h3> <h3>Objectives</h3> To investigate whether the new bone formation (NBF) that is typical of psoriatic arthritis (PsA) can also be detected by ultrasound. In addition, we aimed to investigate whether the presence of NBF and specific autoantibodies could facilitate an earlier diagnosis of psoriatic arthritis. <h3>Methods</h3> Patients fulfilling the CASPAR criteria (Classification Criteria for Psoriatic Arthritis) for PsA were included in the study. X-ray examinations of the hands and feet and standardized ultrasound examination of the hands and feet was performed. Antibody levels of calpastatin, LL37, gliadin, and ADAMTSL5 (Thrombospondin type-1 domain-containing protein 6) were determined by serum ELISA. <h3>Results</h3> Seventy-six patients (51% female) compared to 20 healthy controls (70% female) were included. The median age was 57 years (23-86) and the median disease duration was 10 years (1-54). HLA-B27 was positive in every fourth individual. By X-ray, NBFs were detectable in 55% (n=42) of the patients. In the ultrasound examination, these NBFs were also detectable (Figure 1). In addition, in 18 patients, signs of NBF were detectable due to the increased resolution of the ultrasound examination. Regarding the selected autoantibodies, none of the selected antibodies were associated with the presence of PsA or with PsA related NBFs. <h3>Conclusion</h3> In this study, NBFs were detectable radiographically as well as in the ultrasound examination. As ultrasonography is ubiquitously available in rheumatological offices and represents a gentle examination procedure for the patient, repeated X-ray examinations might be avoided, and regular ultrasound investigations might facilitate an earlier detection of PsA. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> Anna Knothe Grant/research support from: Pfizer Pharma GmbH, Kay-Geert Hermann: None declared, Klaus Frommer: None declared, Ann-Katrin Inderthal Grant/research support from: Pfizer Pharma GmbH, Corinna Heck: None declared, Mona Arnold: None declared, Ingo Tarner: None declared, Walter Hermann: None declared, Carlos Francisco Meneses Villalba: None declared, Elena Neumann: None declared, Ulf Müller-Ladner: None declared, Rebecca Hasseli Grant/research support from: Pfizer Pharma GmbH.